AKT1 and breast carcinoma: The potential mechanisms underlying trastuzumab resistance in breast cancer are the activation of downstream signaling routes, such as the PI3K/AKT and MAPK/ERK pathways, and compensatory activation of signals mediated by other RTKs3,35–37.